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ArginaseAbstract This study aimed to evaluate the protective effect of chitosan (CS) against hypercholes-
terolemia (HC) induced arginase activation and disruption of nitric oxide (NO) biosynthesis using
erythrocytes as cellular model. Human erythrocytes were isolated and classified into eight groups.
Next, cells were treated with L-arginine (L-ARG), Nx-nitro-L-arginine methyl ester (L-NAME), CS
or CS + L-ARG in the presence of normal plasma or cholesterol enriches plasma. Then, erythro-
cytes were incubated at 37 C for 24 h. The present results revealed that, HC induced significant
increase of cholesterol inclusion into erythrocytes membrane compared to control. Moreover,
HC caused significant decrease in nitric oxide synthase (NOS) activity similar to L-NAME; how-
ever, arginase activity and arginase/NOS ratio significantly increased compared to control. On con-
trast, treatment of HC with, L-arginine, CS or CS plus L-arginine prevents HC induced cholesterol
loading into erythrocytes membrane, NOS inhibition and arginase activation. This study suggested
that CS could be protective agent against HC induced disruption of erythrocyte’s oxidative status
and arginase activation.
 2016 Production and Hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1, Saudi
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Arginase is an important regulator of nitric oxide (NO) pro-
duction, and an increase of arginase activity reduces the avail-
ability of L-arginine for NO synthase, thus reducing NO
production, and leading to endothelial dysfunction (Pernow
and Jung, 2013). Increased activity of arginase has been
demonstrated in several pathological conditions including car-
diovascular dysfunction and other vascular diseases (Pernow
and Jung, 2013). Hypercholesterolemia (HC) induces lipemic
stress due to extra cholesterol deposition into the membranes
of vascular cells and erythrocytes, and this triggers reactive
oxygen species (ROS) production, and membrane aberration
(Uydu et al., 2012). Furthermore, lipemic stress is associated
with disruption of L-arginine transport into cells and inactiva-
tion of nitric oxide synthase (NOS), while arginase activity is
increased. Additionally, L-arginine analogues increase, particu-
larly asymmetric dimethylarginine and symmetric dimethy-
larginine (Eligini et al., 2013; Yang et al., 2013; Porro et al.,
2014). The net result of these events is the decrease of NO
levels as a key player in the regulation of homeostasis, vasodi-
lation, neurotransmission, free radicals scavenging and ery-
throcytes function (Eligini et al., 2013).
In past decades, several studies reported that vascular NO is
mostly produced from endothelial cells by endothelial NO syn-
thase (eNOS); however nowadays, erythrocytes were listed as
another major source of NO in vascular lumen (Eligini et al.,
2013; Ramı´rez-Zamora et al., 2013; Porro et al., 2014). For
NObiosynthesis, NOS utilizes L-arginine as substrate; flavopro-
teins and tetrahydrobiopterin were used as coenzymes (Eligini
et al., 2013; Porro et al., 2014). Conversely, arginase competes
with NOS on L-arginine as common substrate; therefore, it
NO production (Yang et al., 2013, Li and Fo¨rstermann,
2013). The proper balance between NOS and arginase is essen-
tial for maintenance of NO homeostasis (Porro et al., 2014;
Yang et al., 2013). Functional erythrocytes have antioxidant
machinery that neutralizes ROS generated in the vasculature;
however, malfunctioned erythrocytes can act as a source of
ROS (Minetti et al., 2007). Moreover, such erythrocytes release
arginase that limits NO production (Porro et al., 2014; Yang
et al., 2013). Therefore, oxidized erythrocytes act as pro-
oxidant bombs to vascular endothelium. Although, several
studies reported that erythrocyte’s arginase activity was aug-
mented by oxidative stress (Yang et al., 2013; Porro et al.,
2014; Li and Fo¨rstermann, 2013), no enough published data
address this topic, and further research are necessary to address
this issue.
Most of lipid-lowering agents have many therapeutic prob-
lems with severe side effects, while dietary fibers as lipid lower-
ing therapy are safer. Chitosan (CS) is a dietary fiber
biodegradable, biocompatible and has many health benefits
including wound healing, antiinflammatory, anti-cancers,
immune-modulator, hemostatic agent, lipid-lowering agent
and antioxidants (Xia et al., 2011; Luo and Wang, 2013;
Anandan et al., 2013). The lipid-lowering effect of CS is attrib-
uted to its binding to fatty acid, cholesterol, and bile salts; this
resulted in delaying the digestion and absorption of fat (Xia
et al., 2011). Additionally, CS augments lipoprotein lipase
activities and influences plasma adipocytokines, which signifi-
cantly reduce adiposity index. Therefore, CS can regulate the
level of circulating triacylglycerol and ameliorates metabolicPlease cite this article in press as: Harisa, G.I. et al., Chitosan treatment abrogates
ceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.05.007alterations (Luo and Wang, 2013). CS can help the body main-
tain the antioxidant activity, such as superoxide dismutase
(SOD), catalase (CAT), glutathione peroxidase (GPx) and
other antioxidants, which play important roles in counterac-
tion of oxidative stress (Xia et al., 2011; Luo and Wang, 2013).
Despite the beneficial effects of CS in hyperlipidemic condi-
tions have been extensively studied, yet no data available
about the effect of CS on arginase activity in HC condition
have been explored. Therefore, the main goal of this study
was to test the hypothesis that CS as innovative therapeutic
agent approaches for treatment of HC induced disruption of
erythrocyte NO biosynthetic pathway. NOS activity and argi-
nase activities were investigated under effect of HC exposure in
the presence and absence of CS.
2. Materials and methods
2.1. Chemicals
Low molecular weight chitosan, L-Arginine (L-ARG), Nx-
nitro-L-arginine methyl ester (L-NAME), and water-soluble
cholesterol were purchased from Sigma–Aldrich (St. Louis,
MO, USA). All other chemicals used were of reagent grade.
2.2. Isolation of erythrocytes and experimental design
Blood samples were drawn from healthy human volunteers by
venipuncture into heparinized test tubes. Plasma sample was
separated by centrifugation at 3000 rpm for 5 min; buffy coat
was removed by aspiration. Then, erythrocytes were gently
washed 3 times with an equal volume of phosphate buffered
saline pH 7.5. Next, supernatant was discarded and erythro-
cytes were separated. Plasma sample was mixed with water-
soluble cholesterol, after this referred to cholesterol-enriched
plasma (HC) (Kanakaraj and Singh, 1989). HC was confirmed
by measuring cholesterol level using cholesterol oxidase
method by commercially available kit (Randox Laboratories,
Crumlin, UK). The protocol for this study conformed to the
guidelines of the Institutional Ethical Committee.
Washed erythrocytes were classified into eight groups as
follows:
Group 1: Normal control (NC), in this group washed ery-
throcytes were incubated with normal plasma (choles-
terol = 150 mg/dl).
Group 2: CS treated group (CS), herein, washed erythro-
cytes were incubated with normal plasma plus CS solution
(1 mg/mL) (Fernandes et al., 2008).
Group 3: In this group cells were treated with L-NAME as
reference group for NO inhibition, in which erythrocytes
were incubated with normal plasma plus (10 mM) of L-
NAME (Kuwai and Hayashi, 2006).
Group 4: L-arginine treated group as reference samples for
NO production, in this group erythrocytes were suspended
in normal plasma plus (10 mM) of L-ARG (Kuwai and
Hayashi, 2006).
Group 5: HC incubated group, in this set erythrocytes were
exposed to HC plasma (cholesterol 450 mg/dl) (Kanakaraj
and Singh, 1989).
Group 6: HC + L-ARG, samples of this group, erythrocytes
were exposed to HC and treated with (10 lM) L-arginine.hypercholesterolemia-induced erythrocyte’s arginase activation. Saudi Pharma-
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were incubated with HC and treated with 1 mg/mL CS.
Group 8: HC+ L-ARG+ CS treated group, herein ery-
throcytes were suspended in HC and treated with combina-
tion of L-ARG and CS group.
All groups were incubated at 37 C for 24 h, and afterward
samples were utilized for the following investigations.
2.3. Percent of cholesterol inclusion
After 24 h incubation time of erythrocytes with plasma sam-
ples in different groups, plasma samples were separated from
erythrocytes by centrifugation, and the percent of cholesterol
inclusion on erythrocytes was calculated as follows:
Cholesterol ðChÞ inclusion % ¼ Ch:Conc:Intial  Ch:Conc:Final
Ch:Conc:Intial
 1002.4. Assay of total antioxidant capacity
Plasma total antioxidant capacity (TAC) was determined using
TAC Assay Kit (Cell Biolabs OxiSelectTM, San Diego, Califor-
nia, USA). This assay is based on the reduction of copper (II)
to copper (I) by uric acid. Upon reduction, the copper (I) ion
further reacts with a coupling chromogenic reagent that pro-
duces a color that measured at 490 nm. Absorbance values
were compared with a known uric acid standard curve. The
assay processes were achieved following manufacturers assay
techniques. TAC was expressed as mM.
2.5. Determination of antioxidant enzymes
Erythrocyte catalase (CAT) activity was determined in ery-
throcyte lysate using the OxiSelectTMcatalase activity assay (Cell
Biolabs, San Diego, California, USA). CAT degrades H2O2 to
water and molecular oxygen, and the amount of degraded
H2O2 is proportional to the enzyme activity. The color change
of the reaction mixture was measured spectrophotometrically
at 520 nm.
GPx activity was measured in hemolysate by RANSELTM
assay Kit (Randox Laboratories, Crumlin, UK). GPx activity
was assessed by oxidation of NADPH to NADP+; the absor-
bance was measured at 340 nm. Glutathione reductase (GR)
activity was measured by using Randox kit (Randox Labora-
tories, Crumlin, UK). This method is based on the reduction
of oxidized glutathione (GSSG) in the presence of NADPH,
which is oxidized to NADP+ and catalyzed by GR. The
decrease in absorbance is measured at 340 nm.
SOD activity in the diluted lysate was measured using com-
mercial RANSODTM assay (Randox Laboratories, Crumlin,
UK). This assay employs xanthine and xanthine oxidase to
generate superoxide radicals which react with 2-(4-iodophe
nyl)-3-(4-nitrophenol)-5-phenyltetrazolium chloride to form a
red dye. The absorbance was determined spectrophotometri-
cally at a wavelength of 505 nm. The assay procedures of were
achieved following manufacturers assay procedures and
expressed as U/g Hb. Hemoglobin was measured in the whole
blood sample by standard laboratory method.Please cite this article in press as: Harisa, G.I. et al., Chitosan treatment abrogates
ceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.05.0072.6. Assay of glutathione
Erythrocytes reduced glutathione (GSH)/Oxidized glu-
tathione (GSSG) contents of erythrocytes were measured
using the method of Hissin and Hilf (1976), using O-
phthalaldehyde (OPT), which forms a fluorescent derivative
with GSH. Briefly, 0.2 mL erythrocyte pellet was diluted
with 0.8 mL distilled water and proteins were precipitated
by addition of 1 mL of 10% trichloroacetic acid (TCA).
The supernatant was used for GSH and GSSG assays.
For GSH assay, 4 mL of reaction mixture consisted of
3.25 mL phosphate–EDTA buffer (0.1 M, pH 8.0), 0.25 mL
O-OPT (1 mg/mL methanol) and 0.5 mL supernatant. The
fluorescence of the GSH-OPT adduct was measured after
15 min using excitation and emission wavelengths of 350
and 450 nm, respectively.
For GSSG assay, N-ethyl maleimide (NEM) was used to
inhibit the oxidation of GSH to GSSG during estimation pro-
cedures, allowing the formation of a stable complex with GSH.
After incubation of 0.5 mL of supernatant with 0.2 mL NEM
(0.04 M) for 30 min, GSSG was measured using the same steps
as the GSH assay, but using 0.1 N NaOH as a diluent instead
of phosphate–EDTA buffer. The quantifications of GSH and
GSSG were calculated using standard GSH and GSSG fluores-
cence and expressed as lM/g hemoglobin.
2.7. Assay of protein carbonyl
The total protein carbonyl content (PCC) in erythrocytes
was determined in hemolysate by a spectrophotometric
method described by Levine et al. (1994). The proteins were
precipitated from hemolysate by addition of 10% TCA. The
precipitate was resuspended in 1.0 mL of 2 M HCl for the
blank control, or in 2 M HCl containing 2% 2,4-
dinitrophenyl hydrazine for the test samples. After incuba-
tion for 1 h at 37 C, protein samples washed with alcohol
/ethyl acetate mixture, and precipitated again by the addi-
tion of 10% TCA. The precipitated protein was dissolved
in 6 M guanidine hydrochloride solution and the absorbance
was measured at 370 nm. The molar extinction coefficient of
22  103 M1 cm1 was used for calculating the PCC level
and expressed as nM of carbonyls formed per mg protein.
The total protein content was determined according to
Lowry et al. (1951), using bovine serum albumin as
standard.
2.8. Assay of malondialdehyde
Concentration of malondialdehyde (MDA) in hemolysate,
an index of lipid peroxidation, was determined spectropho-
tometrically (Ohkawa et al., 1979). A mixture of 200 lL of
8% sodium dodecyl sulfate, 200 lL of 0.9% thiobarbituric
acid, and 1.5 mL of 20% acetic acid were added to a
200 lL supernatant of hemolysate and 1.9 mL of distilled
water was used to make the volume up to 4 mL. After boil-
ing for 1 h, the mixture was cooled and 5 mL of an n-
butanol and pyridine (15:1) solution was added. The mixture
was centrifuged at 5000 rpm for 15 min and the absorbance
was measured at 532 nm. MDA levels were calculated using
tetraethoxypropane as standard.hypercholesterolemia-induced erythrocyte’s arginase activation. Saudi Pharma-
50
Controla
(%
)
4 G.I. Harisa et al.2.9. Assay of sialic acid
Sialic Acid (SA) content of erythrocyte membranes is based on
oxidation of SA to formylpyruvic acid, which reacts with thio-
barbituric acid to form a pink colored product (Denny et al.,
1983). Briefly, membranes (1 mg membrane proteins/mL) were
hydrolyzed in 0.05 M H2SO4 to a final volume of 100 lL for
1 h at 80 C to release SA. Then, the samples were incubated
with 250 lL periodate solution (0.025 M periodic acid in
0.25 M HCl) at 37 C for 30 min. A 250 lL 0.32 M sodium
thiosulphate were added, and the reaction was completed by
addition of 1250 lL 0.1 M thiobarbituric acid. The samples
were heated at 100 C for 15 min and cooled to room temper-
ature with tap water. Finally, 2200 lL acid butanol was added,
mixed, and centrifuged at 1500 rpms in order to extract the
product. The top butanol layer was then collected and assayed
spectrophotometrically at 549 nm. SA standards (N-acetyl
neuraminic acid) ranging from 0 to 50 ng/mL were prepared
and similarly treated to a volume of 100 lL with 0.05 M
H2SO4.
2.10. Determination of NOS activity
Erythrocytes NOS activity assay was performed by monitoring
the rate of conversion of L-ARG into citrulline as described by
Mckee et al. (1994). Erythrocytes hemolysate was incubated
with 0.2 mM L-arginine, 10 mM HEPES, 0.425 mM ethylene-
diaminetetraacetic acid (EDTA), 0.45 mM CaCl2, 80 units of
calmodulin, 1 lM tetrahydrobiopterin, 4 lM flavin adenine
dinucleotide (FAD), 4 lM flavin mononucleotide (FMN),
0.5 mM dithiothreitol (DTT), 0.16 M sucrose and 1 mM
NADPH. One unit of NOS was defined as the amount of
enzyme required to catalyze the conversion of 1 lM of L-
ARG into citrulline/min/mg of protein under assay conditions
used.
2.11. Determination of arginase activity
Erythrocytes arginase activity assessment based on the conver-
sion of L-arginine into urea and ornithine (Kosenko et al.,
2012). The level of urea was determined spectrophotometri-
cally using (Randox Laboratories, Crumlin, UK). The assay
was performed following the manufacturer’s assay procedure.
Erythrocyte’s arginase was expressed as U/g Hb.0
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Figure 1 Effect of CS, L-NAME, L-ARG, HC and CS + L-
ARG on percent of cholesterol inclusion into erythrocytes
membrane compared to normal control. One-way analysis of
variance used for data analysis; Tukey’s posttest was used to
determine the statistical differences between groups. Results were
represented as M± SD (N= 6). Superscript letters indicated
when significant differences observed from either control group or
HC group. a Significantly increase from control. b Significantly
decrease from HC. P 6 0.05.2.12. Determination of nitrite levels
Erythrocytes nitrite levels were determined by using Griess
reagent kit (Cayman, Ann Arbor, USA). Firstly, nitrate was
reduced to nitrite by nitrate reductase as described by Green
et al. (1982). Erythrocytes were hemolyzed by addition of
ice-cold distilled water, and hemoglobin was precipitated by
addition of cold ethanol and chloroform. After vortex, the
mixture was centrifuged at 10,000 rpm for 10 min. One hun-
dred lL of lysate was deproteinized by adding 600 lL of
75 mM ZnSO4 solution. The mixture was stirred, and cen-
trifuged at 10,000 rpm for 5 min at ambient temperature. Then
100 lL of supernatants were added to 40 lL of nitrate reduc-
tase (20 mU), 50 lL of FAD (5 mM), 10 lL of NADPH
(0.6 mM), and 250 lL of phosphate buffer (50 mM). ThePlease cite this article in press as: Harisa, G.I. et al., Chitosan treatment abrogates
ceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.05.007mixtures were incubated for 1 h at 37 C, and then 150 lL of
the mixture was added to 450 lL of Griess reagent and incu-
bated in the dark place for 30 min at room temperature.
Absorbance was measured at 545 nm; nitrite levels were calcu-
lated from sodium nitrite standard curve and expressed in lM.
2.13. Statistical analysis
The statistical differences between groups were analyzed by
one way ANOVA followed by Tukey–Kramer multiple com-
parison test, using GraphPad Prism Software version 5.01.
The values at P 6 0.05 were chosen as statistically significant.3. Results
In the present study, exposure of erythrocytes to HC plasma
induced a significant increase of cholesterol inclusion into ery-
throcytes membrane compared to control ones (P 6 0.01). On
the other hand, treatment of HC group with CS or CS plus L-
arginine significantly decreased cholesterol loading into cell
membranes compared to untreated HC group. Fig. 1 displays
these results. In respect of SOD, GPx, and CAT, these results
indicated that, treatment of control erythrocytes with CS, L-
NAME and L-arginine preserves activity of these enzymes
and their ratios (SOD/CAT and SOD/GPx) at values near that
of control one. However, a significant (P 6 0.05) decrease in
SOD, GPx, and CAT activities was observed in erythrocytes
incubated with HC compared to control. Conversely, treat-
ment of HC group with CS, or CS plus L-arginine preserves
activity of measured enzymes and their ratios compared to
HC group. Table 1 represents these results.
In the current work, HC exposure induced marked decrease
of GSH/GSSG ratio; however, MDA and PCC were signifi-
cantly increased compared to control erythrocytes (P 6 0.05).
On the other side, treatment of HC with CS or CS plus L-
arginine keeps GSH/GSSG, MDA and PCC at values similar
to control group, see Table 2. Erythrocytes SA contents were
significantly decreased by incubation of cell to HC plasma.
However, treatment L-Arginine, CS or CS plus L-arginine pre-
vent HC induces SA loss. Fig. 2 represents these results.hypercholesterolemia-induced erythrocyte’s arginase activation. Saudi Pharma-
Table 1 Effect of HC with or without different treatment on erythrocyte SOD, GPx and CAT and their ratios after compared to
control erythrocytes.
Groups SOD GPx CAT SOD/GPx SOD/CAT
NC 1270 ± 94.6 43.17 ± 4.21 74.80 ± 7.28 29.42 ± 3.83 16.97 ± 1.88
NC+ CS 1374 ± 107 51.98 ± 7.50 79.9 ± 7.30 26.43 ± 4.51 17.20 ± 1.33
NC+ L-NAME 1368 ± 124 50.87 ± 5.59 80.50 ± 6.01 26.89 ± 2.72 16.99 ± 1.84a
NC+ L-ARG 1388 ± 154 55.77 ± 6.39 82.50 ± 7.22 24.89 ± 2.35 16.82 ± 1.72
HC 938.5 ± 81.8a 19.69 ± 3.20a 28..58 ± 3.25a 47.66 ± 5.46b 32.38 ± 3.24b
HC+ L-ARG 1171 ± 125c 37.15 ± 3.79c 64.33 ± 6.28c 31.52 ± 3.34d 18.20 ± 1.55d
HC+ CS 1143 ± 145 c 34.10 ± 5.93c 62.10 ± 5.22c 33.52 ± 2.93d 18.41 ± 1.92d
HC+ L-ARG+ CS 1207 ± 98.6c 41.10 ± 4.91c 68.10 ± 5.22c 29.36 ± 3.10d 17.72 ± 1.67d
One-way analysis of variance used for data analysis; Tukey’s posttest was used to determine the statistical differences between groups. Results
were represented as M± SD (N= 6). Superscript letters indicated when significant differences observed from either control group or HC
group.
P 6 0.05. Units; SOD, GPx and CAT were expressed as U/g Hb.
a Significantly decrease from control.
b Significantly increase from control.
c Significantly higher than HC.
d Significantly lower than HC.
Table 2 Effect of HC with or without different treatment on
erythrocyte GSH/GSSG, MDA and PCO content compared to
control erythrocytes.
Groups GSH/GSSG MDA PCO
NC 44.65 ± 4.41 11.24 ± 1.20 1.79 ± 0. 41
NC+ CS 49.51 ± 0.01 10.91 ± 1.27 1.45 ± 0.23
NC+ L-NAME 50.56 ± 5.33 11.23 ± 0.98 1.52 ± 0.26
NC+ L-ARG 55.39 ± 8.01 10.45 ± 1.10 1.23 ± 0.21
HC 12.17 ± 1.12a 29.20 ± 1.89b 5.24 ± 0.84b
HC+ L-ARG 27.97 ± 3.02c 17.54 ± 1.44d 3.92 ± 0.52d
HC+ CS 29.82 ± 2.54c 15.98 ± 1.15d 2.81 ± 0.45d
HC+ L-ARG+ CS 35.92 ± 3.41c 12.71 ± 1.73d 2.14±.0.55d
One-way analysis of variance used for data analysis; Tukey’s
posttest was used to determine the statistical differences between
groups. Results were represented as M± SD (N= 6). Superscript
letters indicated when significant differences observed from either
control group or HC group.
P 6 0.05. Units; GSH and GSSG expressed as lM/g Hb MDA,
lM; PCO, nM mg/protein and nitrite, lM.
a Significantly decrease from control.
b Significantly increase from control.
c Significantly increase from HC group.
d Significantly decreased from HC group.
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Figure 2 Effect of CS, L-NAME, L-ARG, HC and CS + L-
ARG on sialic acid content of erythrocyte membrane compared to
control erythrocytes. One-way analysis of variance used for data
analysis; Tukey’s posttest was used to determine the statistical
differences between groups. Results were represented as M± SD
(N= 6). Superscript letters indicated when significant differences
observed from either control group or HC group. a Significantly
decrease from control. b Significantly increase from HC. P 6 0.05.
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Figure 3 Effect of CS, L-NAME, L-ARG, HC and CS + L-
ARG on plasma total antioxidant status compared to control
plasma. One-way analysis of variance used for data analysis;
Tukey’s posttest was used to determine the statistical differences
between groups. Results were represented as M± SD (N= 6).
Superscript letters indicated when significant differences observed
from either control group or HC group. a significantly decrease
from control. b significantly increase from HC. P 6 0.05.
Chitosan and arginase activity in Hypercholesterolemia 5Plasma TAC significantly decreased in HC group compared to
control. However, no significant difference was noted between
control and control treated with CS or CS +
L-arginine. Treatment of HC group with CS or Cs +
L-arginine prevents HC-induced TAC depletion. Fig. 3 anno-
tates these results.
In respect of NO variables, the exposure of erythrocytes to
L-NAME caused a significant decrease in NOS activity and
NO level compared to control group. A similar result was
observed in HC treated group. On the other side, L-arginine
treatment induced a significant increase in NOS activity com-
pared to control; however, CS induces a marked but non-Please cite this article in press as: Harisa, G.I. et al., Chitosan treatment abrogates hypercholesterolemia-induced erythrocyte’s arginase activation. Saudi Pharma-
ceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.05.007
6 G.I. Harisa et al.significant increase of NOS compared to control group. L-
arginine treatment alone fails to prevent HC induced NOS
inactivation. However, treatment of HC with L-arginine
+ CS prevented HC-induced decrease in NOS activity. By
contrast, arginase activity was increased by HC exposure;
however, CS or CS plus L-arginine treatment prevents HC
induced arginase activation. Similar results were observed for
arginase/NOS ratio. Table 3 explains these data.
4. Discussion
Previous studies reported that an increase in arginase activity
plays a crucial role in the cardiovascular pathobiology, so that
the inhibition of arginase may protect against vascular diseases
(Rabelo et al., 2015). Therefore, this study was conducted to
explore the protective role of CS against HC induced erythro-
cyte’s arginase activation. HC disrupts erythrocytes cholesterol
homeostasis, triggers ROS production and depletes antioxi-
dant capability of cells (Devrim et al., 2008). However,
cholesterol-lowering therapy prevents HC induced erythro-
cytes dysfunction (Franiak-Pietryga et al., 2009; Uydu et al.,
2012). Herein, incubation of erythrocytes with cholesterol
enriches plasma increased cholesterol inclusion into erythro-
cytes. Similar results were documented in several previous
studies (Uydu et al., 2012; Harisa and Badran, 2015). In con-
trary, CS prevents cholesterol deposition into erythrocyte
membranes; similarly, it has been reported that cholesterol
lowering therapy decreases erythrocytes membrane cholesterol
(Uydu et al., 2012). The attraction between CS and cholesterol
decreases cholesterol inclusion into erythrocytes membrane.
In the current study, SA was assessed to confirm the safety
of CS addition to erythrocytes SA as well as SA elicits antiox-
idant action. It has been reported that, ROS induced desialyla-
tion by depletion of SA content from cell surfaces (Pawluczyk
et al., 2014; Harisa, 2015). Therefore, significant decrease in
SA content was noticed in cells incubated with high choles-
terol. The decreases of erythrocytes SA content increase their
friction among themselves and endothelial cells; this may trig-Table 3 Effect of HC with or without different treatment on eryt
content compared to control erythrocytes.
Groups NOS Argina
NC 1.83 ± 0.24 20.82 ±
NC+ CS 1.94 ± 0.54 18.24 ±
NC+ L-NAME 0.71 ± 0.22a 21.27 ±
NC+ L-ARG 2.20 ± 0.41 27.92 ±
HC 0.87 ± 0.11a 39.78 ±
HC+ L-ARG 1.04 ± 0.23b 27.92 ±
HC+ CS 1.43 ± 0.26b 24.87 ±
HC+ L-ARG+ CS 1.74 ± 0.44b 21.92 ±
One-way analysis of variance used for data analysis; Tukey’s posttest was
were represented as M± SD (N= 6). Superscript letters indicated whe
group.
P 6 0.05. Units; NOS expressed as U/mg protein, arginase U/g Hb and
a Significantly decrease from control.
b Significantly increase from HC.
c Significantly increase from NC group.
d Significantly decreased from HC group.
Please cite this article in press as: Harisa, G.I. et al., Chitosan treatment abrogates
ceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.05.007ger vascular dysfunction (Fan et al., 2012). By contrast, treat-
ment with CS keeps SA levels at values near that of control.
This is in agreement with many studies which demonstrated
that CS preserves antioxidants capacity (Anandan et al.,
2013). In the present study, plasma TAC levels were signifi-
cantly decreased by HC incubation. Likewise, several studies
reported that oxidative stress exposure induced decline of
TAC levels. The decrease in plasma TAC was demonstrated
in HC induced oxidative stress (Devrim et al., 2008). Oxidative
stress environment causes a plethora of changes in erythrocytes
including loss of antioxidant power and enhances proteins and
lipids oxidation.
Ramı´rez-Zamora et al. (2013), reported that erythrocyte
membranes are the most targets for deleterious actions of
ROS. The equilibrium between SOD as hydrogen peroxide
producing agent as well as CAT, and GPx as hydrogen perox-
ide degrading agents is essential for the removal of ROS. The
activity ratios were calculated to better assess antioxidant
defenses. Herein, oxidative stress in erythrocytes was increased
as confirmed by increase of SOD/CAT and SOD/GPx ratios,
GSSG, PCC and MDA in erythrocytes exposed to HC. Simi-
larly, several studies demonstrated that exposure of erythro-
cytes to HC induced a decrease of antioxidant power;
however, biomolecular damage was increased (Devrim et al.,
2008; Franiak-Pietryga et al., 2009; Uydu et al., 2012). This
attributed to elevation of ROS that consumes antioxidant
machinery. Consequently, oxidized GSH, MDA and PCC
levels were increased. CS treatment ameliorates these oxidative
alterations in erythrocytes by its antioxidant activity. Antioxi-
dant properties of CS are not only confirmed by in vitro stud-
ies, but also demonstrated in many in vivo studies using animal
models as well as clinical trials. Treatment with CS preserves
antioxidant enzymes, particularly glutathione-dependent sys-
tem, increases in antioxidant potential, and restores redox bal-
ance. Therefore, CS decreases lipids and proteins oxidation
and attenuates cellular damage (Luo and Wang, 2013).
HC disrupts NO homeostasis through increase of ROS for-
mation, depletion of NOS substrate, and oxidation of cofac-hrocyte NOS, arginase activity, arginase/NOS ratio and nitrite
se Arginase/NOS Nitrite
1.52 12.47 ± 1.11 586.8 ± 94.14
1.21 9.40 ± 0.94 604.6 ± 89.47
2.11 29.96 ± 1.21 407.0 ± 76.89a
1.71 12.96 ± 1.87 720.1 ± 98.47c
3.14c 45.72 ± 4.52c 278.3 ± 44.56a
2.43d 26.84 ± 1.75d 322.4 ± 66.85
2.84d 17.27 ± 1.81d 422.7 ± 74.58b
1.97d 12.60 ± 1.43d 543.6 ± 91.77b
used to determine the statistical differences between groups. Results
n significant differences observed from either control group or HC
nitrite lM.
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ous studies have demonstrated that inhibition of arginase
increases NO level, and decreases risk of ischemic heart dis-
eases (Pernow and Jung, 2013). The finding of the present
study confirmed that HC induced NOS inactivation compared
to control cells. These results are in agreement with the finding
of Devrim et al. (2008) who reported that HC decreases NOS
activity and NO production. Likewise, Ramı´rez-Zamora et al.
(2013) reported ROS inactivates NOS. The increase of choles-
terol inclusion into cell membrane impairs entry of L-Arginine
as NOS substrate into the cells (Eligini et al., 2013). Con-
versely, CS restores NOS activity and nitrite level compared
to HC treated cells. These results were concurred with several
studies which demonstrated that CS improves NO level
(Ozcelik et al., 2014; Zhang et al., 2014). Moreover, numerous
studies reported that cholesterol lowering therapy improves
NO bioavailability (Harisa et al., 2012; Li and Fo¨rstermann,
2013).
The current investigations revealed that arginase activity
and arginase/NOS ratio were increased by HC exposure. Sim-
ilarly, Ramı´rez-Zamora et al. (2013) reported that oxidative
stress induced arginase activation. Furthermore, Yang et al.
(2013) indicated that ROS augments arginase activity. In such
cases, L-arginine availability was limited; therefore, NO pro-
duction decreases. On the contrary, treatment of HC with
CS or CS plus L-arginine prevents HC-induced arginase activa-
tion. Similar observation was indicated by Schnorr et al.
(2008), who suggested antioxidants treatment diminishes argi-
nase activity in erythrocytes with an increase of NO
bioavailability.
5. Conclusion
In conclusion, this study confirmed HC increased cholesterol
inclusion into erythrocytes membrane, and this accelerates
oxidative stress in erythrocytes. CS could be effective therapeu-
tic agent against HC induced erythrocytes dysfunction by its
hypocholesterolemic effect, antioxidant activities as well as
normalization of arginase activity and restoration of NO
homeostasis. Further in vivo studies are required to confirm
this matter.
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